US announces support of COVID-19 vaccine IP waiver, though WTO negotiations likely to take months. Our experts weig… https://t.co/A09BhLWtWz
ESG criteria in tendering landscape shows wide variation between top-5 European countries
A trend toward European procurement countries adding environmental sustainability to tender criteria for pharmaceuticals and medical devices continued to gain importance during 2020. Our ProcureIntel analysis highlights growing space for the inclusion of environmental criteria in the top-5 European markets between 2014 and 2020. Increases in the use of ESG-criteria in pharmaceutical and medical equipment tenders in 2020 climbed well above recent annual averages. This is despite contract notices with environmental specifications still being below a 2019 peak. The slight dip in 2020 activity is almost certainly a consequence of COVID-19's impact on the market. Evidence gleamed from ProcureIntel data hints at the likelihood that certain European governments opted to use temporary exemptions from ESG award criteria to facilitate urgent procurements of medical resources.
The move toward higher numbers of tenders with ESG-linked components is subtle. All indications are that the European pharmaceutical and medical equipment tender procurement market is not on the verge of a revolution toward "green" criteria. But there is upward momentum, and increased effort by purchasers, to incorporate environmental calculations, albeit progress is gradual and lower price criteria continue to be the substantially more important factor especially for the pharmaceutical market.
Between 2014 and 2020 there were a combined total of 2,304 and 1,302 contract notices with environmental specifications of medical equipment and pharmaceuticals, respectively, from buyers in France, Germany, Spain, Italy and the United Kingdom according to ProcureIntel. The seven-year average works out at 329 and 186 tenders per year for medical equipment and pharmaceuticals. This compares to 414 contract notices with ESG criteria for medical devices and 241 for medicines in 2020.
Variations between the top-5 European countries appear to have expanded slightly in 2020. French medicine tender notices with environmental specifications fell from 49 last year to 31 in 2020, whereas medical device tender notices with environmental specifications declined from 144 to 138 in 2020. ESG-referenced tenders for medical equipment supplies in Italy during 2020 amounted to 33, which was slightly higher than an annual average of 31 since 2014 but still below a peak of 37 in 2019. The same is true in the pharmaceutical segment, with ProcureIntel observing 10 contract notices containing ESG criteria, as opposed to an annual average since 2014 of 12 and a peak of 14 during 2019.
Contradicting the relative reductions seen in France and Italy, ESG specifications for pharmaceutical tenders in Spain climbed 39% year-on-year (y/y) from 38 in 2019 to 53 in 2020. Spain's medical equipment tenders involving ESG specification also rose 50% y/y from 103 in 2019 to 155. Germany too offered above average contract notices containing ESG specifications for medical equipment and pharmaceutical tenders, with those for pharmaceuticals standing at 131 (versus a yearly average of 86), while those for medical devices amounted to 28 (as opposed to a yearly average since 2014 of 26).
A basic calculation of pharmaceutical tenders with environmental considerations tenders versus total tenders reveals that France (11.2%) continues to have the highest overall share, followed by Germany (10.9%), the UK (10.2%), Spain (4.9%) and Italy (4.5%). As such, Italy and Spain continue to stand somewhat apart with a conspicuously low level of ESG criteria embedded into the tendering landscape. This is steadily changing, notably in the case of Spain. The German market is where the gap between "green tenders" and price-driven tenders has been growing the most significantly, with pricing becoming more and more important, thereby widening the gap with environmental criteria.
Looking ahead to 2021, the most important development in this sphere is set to be the UK's implementation from January of the new the Procurement Policy Note (PPN) 06/20. A core tenet of the PPN sets out new requirements on "social value" when assessing tenders, including environmental and climate change goals upon which a public contract might be evaluated. The prior Public Services (Social Value) Act 2012 merely required contracting authorities "consider" social value elements when setting award criteria and assessing tenders for public sector contracts. While the scope of the requirement is something of a grey area, and there appear to be certain exemptions that could be invoked, nevertheless the social value model will mean the incorporation of ESG criteria becomes increasingly standard practice. A minimum 10% weighting will apply, but with flexibility for higher weightings.
The momentum that is set to build in 2021 and beyond for ESG tender award criteria presents the pharmaceutical industry with a complex array of challenges and potentially increased scrutiny of the sectors environmental footprint, not only on the European manufacturing scene but also internationally. The new mixture of pricing and ESG criteria that is on display in the European tender environment for medicines and medical devices is not only occurring in France, Germany, Italy Spain and the United Kingdom. There is growing evidence from the Nordic region that tenders which include environmental and sustainability criteria is fast increasing also. The latest evidence comes from the Nordic joint tender procurement initiative - involving Denmark, Iceland and Norway - confirming that criteria for winning tender contracts at the next 2021 competition will include qualitative criteria on the environment. The outlook for suppliers is that significant investments in environmental standards will be likely be needed to compete for European tenders in future. The changing environment may give an advantage to manufacturers in Europe and North America, at the expense of China and India where ESG standards may take longer to adjust. An expectation there will be a slight, but tangible, reduced focus on primary price award criteria and a higher weighting given to ESG over the medium-term outlook may also benefit smaller and medium-sized companies, which may be able to remain more competitive than today.
- US announces support of COVID-19 vaccine IP waiver
- Why are pharma prices changing?
- Supply chain resilience and the cost to pharmaceutical trade
- Japan’s new CEA-based price adjustments set to maintain pricing pressure on innovative drugs
- Vaccine hesitancy boosts risks from vaccine nationalism
- The risks of vaccine nationalism
- Unlocking biomarker diagnostics in Europe and the win-win for the innovative oncology sector
- Biden administration scores first legislative win for pharmaceutical pricing reform
We use our inhouse data and visualization tool to understand the reasons behind medicines price changes. here is h… https://t.co/C5jgbZXHAV
As governments look to accelerate efforts to onshore production of essential products due to the COVID-19 pandemic,… https://t.co/50dJgGycL3